How much has Guardant Health raised?
Guardant Health is a public company (Nasdaq: GH), so the most useful current funding read is its filings, revenue scale, cash flow, guidance, and acquisition capacity rather than private round totals.
- Total raised
- Public company; private total not the current constraint
- Disclosed rounds
- Pre-IPO/private history plus public filings
- Latest round
- Public-market financing and operating cash flow
- Latest valuation
- Nasdaq: GH
- First raised
- 2012
- Notable backer
- Public shareholders
Guardant Health's funding rounds
Guardant Health's capital path moved from founding and growth capital into public-company financing.
- 2012FoundedGuardant Health is founded to advance blood-based cancer diagnostics.
- 2018IPOGuardant lists on Nasdaq under GH.
- 2020FDA approvalGuardant360 CDx receives FDA approval for comprehensive genomic profiling.
- 2024Shield approvalShield becomes an FDA-approved blood-based colorectal cancer screening test.
- 20262026 outlookGuardant guides to $1.25B-$1.28B of 2026 revenue.
Sources:Guardant 2025 results and 2026 outlookGuardant annual reports
How much has Guardant Health raised in total?
Guardant Health is best analyzed as a public company as of June 2026. Any pre-IPO venture or private-equity history is less useful for current selling than the company's listed status, revenue base, cash generation, debt capacity, and investor commitments.
The current scale marker is 2026 revenue guidance of $1.25B-$1.28B. That tells sellers the company can fund enterprise purchases, but those purchases must survive budget ownership, procurement, security, compliance, and ROI review.
Who are Guardant Health's investors?
The relevant investor base is the public shareholder base behind Nasdaq: GH. Management teams at this stage are accountable to public-market expectations for growth, margin, cash flow, guidance, and risk control.
That accountability affects buying behavior: projects tied to reported metrics, margin expansion, regulatory readiness, or customer growth are easier to justify than speculative tooling.
Why did valuation or capital priorities move?
Valuation for a public healthcare company moves with growth, margins, reimbursement, utilization, clinical evidence, customer retention, regulatory risk, and capital-market sentiment. Guardant Health's latest public materials emphasize 2026 revenue guidance of $1.25B-$1.28B, which is the clearest factual anchor for current account planning.
For seller strategy, avoid treating valuation as the budget. Translate the company's stated operating priorities into a business case owned by a specific executive function.
Is Guardant Health profitable, and will it need more capital?
Profitability and capital needs should be read from the latest annual report, quarterly results, cash-flow statement, and guidance. Public healthcare and life-science companies can have revenue scale while still prioritizing profitability, cash preservation, restructuring, R&D, or commercial expansion.
The safe sales assumption is mature budget governance: finance will ask why the project matters now, what metric it moves, and how implementation risk is controlled.
What does Guardant Health's funding mean if you sell into them?
The seller signal is buying capacity with a high proof bar. Guardant Health can fund software, data, services, infrastructure, compliance, clinical, and go-to-market projects when they match a board-visible or executive-visible priority.
Procurement is likely to favor vendors with healthcare references, security documentation, integration readiness, implementation support, and clear commercial terms.
As of June 2026.Sources:Guardant 2025 results and 2026 outlookGuardant annual reports
Guardant Health — frequently asked questions
